-
Journal of HIV Therapy
- Publisher:
- Mediscript Ltd.
- Publication date:
- 2009-05-27
- ISBN:
- 1462-0308
- Copyright:
- COPYRIGHT TV Trade Media, Inc.<br/>COPYRIGHT GALE, Cengage Learning. All rights reserved.
Issue Number
- Vol. 15 Nbr. 1, March 2010
- Vol. 14 Nbr. 3, November 2009
- Vol. 14 Nbr. 2, June 2009
- Vol. 14 Nbr. 1, March - March 2009
- Vol. 13 Nbr. 4, December 2008
- Vol. 13 Nbr. 3, September - September 2008
- Vol. 13 Nbr. 2, June 2008
- Vol. 13 Nbr. 1, March 2008
- Vol. 12 Nbr. 4, December 2007
- Vol. 12 Nbr. 3, September 2007
- Vol. 12 Nbr. 2, June 2007
Latest documents
- HIV immunology: what lessons can we learn from recent vaccine trials?
- Lymphocyte activation in HIV-1 infection: time for quality control.
- SILCAAT and ESPRIT: taking stock.
- Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.
- A review of the use of activation markers in Africa.
- HIV as an inflammatory disease.
- HIV, atherosclerosis and inflammation: implications for treatment.
- Immune activation and the pathogenesis of HIV disease: implications for therapy.
- Inflammation and gut permeability.
- Lymphoid and histiocytic proliferations in HIV-positive patients: problems in diagnosis.
Featured documents
- HIV immunology: what lessons can we learn from recent vaccine trials?
- Differentiating HIV-associated non-Hodgkin's lymphomas with similar plasmacellular differentiation.
- Targeting the HIV integration process in antiviral therapy.
- Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.
- New drugs.
- Immune activation and viraemia: reciprocal interactions in disease pathogenesis.
- Lymphocyte activation in HIV-1 infection: time for quality control.
- The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
- A review of the use of activation markers in Africa.
- Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections.